COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that its partner, Bharat Biotech, posted positive results from a Phase 2 analysis of the vaccine candidate, COVAXIN™ (BBV152), in participants ages …
COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety Read More